954Curated trials
Sample Evidence Brief · Current DATA10
Alzheimer's Disease:
current evidence, not a stale snapshot.
Alzheimer evidence brief from the current NeuroRisk curated corpus: 954 trials, 213 recruiting, 536 sponsors and 61 countries.
Generated 2026-10-29 06:18 UTC. Counts are current indexed-corpus values, not claims of exhaustive global totals.
213Recruiting
536Sponsors
61Countries
Leading sponsors
Massachusetts General Hospital14indexed trials
Avid Radiopharmaceuticals14indexed trials
Eli Lilly and Company12indexed trials
Johns Hopkins University11indexed trials
Pfizer11indexed trials
Merck Sharp & Dohme LLC10indexed trials
National Institute on Aging (NIA)10indexed trials
National Taiwan University Hospital9indexed trials
Hoffmann-La Roche9indexed trials
Wyeth is now a wholly owned subsidiary of Pfizer9indexed trials
Leading geographies
United States462indexed trials
France117indexed trials
Canada92indexed trials
United Kingdom77indexed trials
Spain70indexed trials
Germany60indexed trials
Italy59indexed trials
Australia53indexed trials
China44indexed trials
Sweden44indexed trials
Source trail
Clinical trial evidence: ClinicalTrials.gov NCT records. Disease normalization: structured conditions + MeSH-linked NeuroRisk DATA10 ontology. Each NCT below links to the source registry.
Methodology →Example trial evidence
NCT07869264An Observational Study of LEQEMBI in Routine Clinical Practice in TaiwanNOT_YET_RECRUITING
NCT07786116The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological ConditionsRECRUITING
NCT07781345A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)NOT_YET_RECRUITING
NCT07779863Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's DiseaseNOT_YET_RECRUITING
NCT07752784Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.RECRUITING
What this sample proves
The report exposes the current data snapshot, source IDs, generation time, scope and limitations. Enterprise reports add comparisons, research evidence, provenance tables and decision-oriented synthesis.
Limitation
This is research and market intelligence. It is not medical advice, a regulatory opinion, an investment recommendation or a guarantee of clinical/commercial outcome.